# Overcome Cancer Cell Drug Resistance Using Natural Products

Authors: Pu Wang; Hua Li Yang; Ying Juan Yang; Lan Wang; Shao Chin Lee
Journal: Evidence-Based Complementary and Alternative Medicine
 (2015)

---

## Abstract

Chemotherapy is one of the major treatment methods for cancer. However, failure in chemotherapy is not uncommon, mainly due to dose-limiting toxicity associated with drug resistance. Management of drug resistance is important towards successful chemotherapy. There are many reports in the Chinese literature that natural products can overcome cancer cell drug resistance, which deserve sharing with scientific and industrial communities. We summarized the reports into four categories: (1)in vitro studies using cell line models; (2) serum pharmacology; (3) in vivo studies using animal models; and (4) clinical studies. Fourteen single compounds were reported to have antidrug resistance activity for the first time. In vitro, compounds were able to overcome drug resistance at nontoxic or subtoxic concentrations, in a dose-dependent manner, by inhibiting drug transporters, cell detoxification capacity, or cell apoptosis sensitivity. Studies in vivo showed that single compounds, herbal extract, and formulas had potent antidrug resistance activities. Importantly, many single compounds, herbal extracts, and formulas have been used clinically to treat various diseases including cancer. The review provides comprehensive data on use of natural compounds to overcome cancer cell drug resistance in China, which may facilitate the therapeutic development of natural products for clinical management of cancer drug resistance.


---

## Body

## 1. Introduction

Cancer is one of the most common noncommunicable diseases and one of the leading causes of death worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012, which are expected to rise in the future [1]. In China, according to the Annual Cancer Registry in 2013, more than 3 million new cases were diagnosed with cancer, which is equivalent to 6 patients diagnosed per minute, and the prevalence has been increasing. This casts great socioeconomic burdens. Despite the fact that chemotherapy is central to clinical management of cancer, failure in chemotherapy is not uncommon, mainly due to the dose-limiting toxicities, which is associated with the occurrence of drug resistance. Cancer cell drug resistance occurs in inherited or acquired manners. Inherited drug resistance is the initial unresponsiveness of cancer to a specific drug, while acquired resistance refers to emerged drug resistance after initial successful drug treatment. No matter whether it occurs before or after chemotherapy, how to overcome drug resistance is a key issue for cancer management, which has been under investigation. Taking nanomedicine, for example, scientists have been trying to deliver drugs to cancer cells by nanoparticles, which may provide an approach to overcome drug resistance [2], as nanoparticles are hoped to enhance drug permeability, retention, and intracellular accumulation as well as increase drug circulating time. Amongst various nanoparticles, ThermoDox is currently under phase III clinical trial, which is a type of lipid-based nanoparticle that uses polyethylene glycol to increase circulation time. There are also clinical trials that use dendrimers to deliver chemodrug to treat different cancers such as breast cancer, non-small cell lung cancer, and advanced pancreatic cancer. Apart from the modern technologies, use of chemical compounds to counteract drug resistance is another strategy, for which natural products may be useful. Indeed, natural products provide a useful resource for drug development. About 36% of the small molecule compounds approved by US Food and Drug Administration between 1999 and 2008 are natural products or their derivatives [3]. In the past years, there is an emerging view that targeted therapies are superior to traditional chemotherapy, which seems to promote the development of targeted therapy, leaving the therapeutic development of natural compounds more or less being ignored. Unfortunately, the drawbacks of targeted therapy start to appear after years in practice [4]. Majority of cancers are not targetable, as they show disturbances in multiple oncogenic pathways and adaptive mechanisms that limit the efficacy of targeted therapy, and the treatment benefit using targeted therapy is often less than 6 months. Combination treatment using multiple targeted therapeutic agents may not be better; it can have greater unacceptable toxicity than clinical benefits. Thus, the natural products have come back to the spot light in the area of cancer management; 12 natural products and derivatives have been approved for cancer treatment since 2007. Some natural compounds such as quercetin and curcumin are under clinical trials to overcome cancer drug resistance [5]. In China, in particular, possibly due to the long history of using natural compounds in clinical management of disease including cancer, as is practiced in Traditional Chinese Medicine, there are many reports on overcoming cancer drug resistance using natural compounds. These investigations have produced abundant informative data, which are unlikely to be commonly known to other scientific and industrial communities. Sharing the information is likely to be appreciated.This review summarizes and discusses the studies on the use of natural products to overcome cancer drug resistance, which were published in the Chinese literature. These studies are organized into four categories: (1)in vitro studies using various cell line models; (2) serum pharmacology studies that test the antidrug resistance effects of serum samples from animals fed with natural products; (3)in vivo studies that use animal models bearing tumor xenografts or transplantable tumor cells; and (4) clinical studies that give natural products to patients in addition to conventional chemotherapy, in comparison with patients who receive conventional chemotherapy alone.We are aware that there are many excellent works in this area published in English. They have been reviewed, including a review by Cort and Ozben this year [6]. There are also Chinese authors who publish reports in English rather than Chinese journals. For example, Zhang and coworker show that a synthetic derivative of 23-hydroxybetulinic acid can reverse cancer cell multidrug resistance [7]. Guo et al. note that β-Elemene can reverse multidrug resistance mediated by the ABCB1 transporter [8]. Moreover, marine drugs can provide promising candidates for reversal of cancer cell drug resistance, such as lamellarin O [9] and sipholenol A [10]. These informative data are not included in this review.


## 2. Mechanisms of Drug Resistance

Cancer chemoresistance occurs through various biological mechanisms that include drug efflux, inhibition of cell death, detoxification, DNA damage repair, alternation of drug targets, stem cells, and epithelial to mesenchymal transition [11, 12]. Amongst these mechanisms, drug efflux, cell death inhibition, and detoxification are commonly studied, which are relevant to this review (Figure 1).Figure 1
Mechanisms underlying the development of cancer cell drug resistance.


### 2.1. Drug Efflux

A family of proteins can expel drugs out of cancer cells and decrease the intracellular drug concentration, thereby preventing the drug toxicity. The human genome encodes 48 members of such proteins called ATP-binding cassettes (ABC), which fall into ABCA to ABCG 7 subgroups, with 15 of them being associated with drug resistance. These proteins are believed to be the major players in the development of cancer cell chemoresistance [13]. The best characterized ABC proteins are MDR1 (p-glycoprotein), multidrug resistance-associated proteins (MRPs), and breast cancer resistant protein (BCRP). MDR1 is the first ABC member discovered with a role in drug resistance. It is expressed in nearly all tissues and has been found to mediate drug resistance in many cancers including breast, colon, gastric, kidney, leukemic, liver, and pancreatic cancer [14]. MRPs represent the largest branch of ABC transporters. This subgroup of proteins includes nine efflux transporters (MRPs1–9), one gated chloride channel, and two potassium channel regulators [8], with MRP1 as the founding member. MRP1 is ubiquitously found in a number of human cells, the elevation of which is associated with drug resistance in many types of cancer. BCRP was first cloned from drug resistant human breast cancer cells, whereby it gets the name [15], which is expressed in many types of cells [16].


### 2.2. Inhibition of Cell Death

Apoptosis is the major type of cell death triggered by chemodrugs. There are two established pathways of apoptosis. The intrinsic pathway centers on mitochondria. Apoptotic signals recruit proapoptotic molecules such as Bax to mitochondria, followed by triggering mitochondria to release cytochrome c that leads to activation of downstream caspases which are apoptosis effectors to cause cell damage. There are also antiapoptotic factors that play an important part in the decision of life or death, which include Bcl-2 and Akt. Bcl-2 is located on mitochondria, which can inhibit cytochrome c release. The extrinsic pathway is activated by binding of ligand to death receptor on cell surface, which activates caspase-8 and then downstream caspases. Bcl-2 and Akt as well as NF-κB are found to be highly expressed in some type of cancers, which are associated with drug resistance. Akt itself is a protein kinase which is activated by PI3 kinase. Once activated, Akt can regulate a variety of apoptosis signal mediators to inhibit apoptosis. It can phosphorylate IκB, which results in NFκB activation that promotes survival and Bad phosphorylation/inactivation to block apoptotic signal. In addition, phosphorylation of caspase-9 by Akt also blocks the induction of apoptosis, and both Akt and NFκB can activate Bcl-2 to inhibit cytochrome c release from mitochondria [17]. Suppression of proapoptotic proteins such as Bax is also associated with the occurrence of drug resistance. In the clinical setting, upregulation of antiapoptotic proteins (i.e., Bcl-2) and downregulation of proapoptotic proteins (i.e., Bax) are found to be associated with poor prognosis of cancer patients [11, 18], which supports a causal role of apoptosis inhibition in the occurrence of cancer cell drug resistance.


### 2.3. Detoxification

GSH-GST system is one of the major detoxification mechanisms, which is in relevance to the development of drug resistance [19]. Levels of GSH and GST activity are in positive correlation with cancer stage [20]. Protein level of GSTπ, in particular, is found to be associated with chemoresistance in patients with different cancers [21–23]. In the clinical setting, GST gene polymorphisms are associated with the development of different cancers [24] and the response of cancer patients to chemotherapy [25]. These observations support a role of GSH-GST system in the regulation of cancer cell response to chemodrugs.GSH is a small peptide composed of glutamate, cysteine, and glycine. It is an important cellular antioxidant that can suppress oxidative stress to maintain normal cellular redox homeostasis, which relies on its conjugation properties of the sulfhydryl moiety of the cysteine residue. GSH has the ability to directly scavenge cellular reactive oxygen species in a nonenzymatic manner. Alternatively, it serves as a cofactor for GSH peroxidase in the reduction of H2O2 and other peroxide species. The GSTs are classical phase II metabolic enzymes including GSTπ. They can detoxify xenobiotics via conjugation of reduced GSH with the electrophilic center of a large spectrum of hydrophilic molecules. Although GSH-GST system helps in the maintenance of normal redox homeostasis and the protection against oxidative damage, it has adverse effect in chemotherapy, as it is also intimately involved in the detoxification of numerous xenobiotics. GST family of enzymes utilize GSH as a cofactor in the phase II metabolism of various chemotherapeutic agents, resulting in the formation of GSH-drug conjugates that are more water soluble than their parent compounds and therefore are easier for transporter-mediated efflux. Unfortunately, many chemodrugs are substrates of GSTs. This explains why elevated level/activity of intracellular GSH-GST system is often implicated in the development of cancer cell resistance to various chemodrugs [2].


## 2.1. Drug Efflux

A family of proteins can expel drugs out of cancer cells and decrease the intracellular drug concentration, thereby preventing the drug toxicity. The human genome encodes 48 members of such proteins called ATP-binding cassettes (ABC), which fall into ABCA to ABCG 7 subgroups, with 15 of them being associated with drug resistance. These proteins are believed to be the major players in the development of cancer cell chemoresistance [13]. The best characterized ABC proteins are MDR1 (p-glycoprotein), multidrug resistance-associated proteins (MRPs), and breast cancer resistant protein (BCRP). MDR1 is the first ABC member discovered with a role in drug resistance. It is expressed in nearly all tissues and has been found to mediate drug resistance in many cancers including breast, colon, gastric, kidney, leukemic, liver, and pancreatic cancer [14]. MRPs represent the largest branch of ABC transporters. This subgroup of proteins includes nine efflux transporters (MRPs1–9), one gated chloride channel, and two potassium channel regulators [8], with MRP1 as the founding member. MRP1 is ubiquitously found in a number of human cells, the elevation of which is associated with drug resistance in many types of cancer. BCRP was first cloned from drug resistant human breast cancer cells, whereby it gets the name [15], which is expressed in many types of cells [16].


## 2.2. Inhibition of Cell Death

Apoptosis is the major type of cell death triggered by chemodrugs. There are two established pathways of apoptosis. The intrinsic pathway centers on mitochondria. Apoptotic signals recruit proapoptotic molecules such as Bax to mitochondria, followed by triggering mitochondria to release cytochrome c that leads to activation of downstream caspases which are apoptosis effectors to cause cell damage. There are also antiapoptotic factors that play an important part in the decision of life or death, which include Bcl-2 and Akt. Bcl-2 is located on mitochondria, which can inhibit cytochrome c release. The extrinsic pathway is activated by binding of ligand to death receptor on cell surface, which activates caspase-8 and then downstream caspases. Bcl-2 and Akt as well as NF-κB are found to be highly expressed in some type of cancers, which are associated with drug resistance. Akt itself is a protein kinase which is activated by PI3 kinase. Once activated, Akt can regulate a variety of apoptosis signal mediators to inhibit apoptosis. It can phosphorylate IκB, which results in NFκB activation that promotes survival and Bad phosphorylation/inactivation to block apoptotic signal. In addition, phosphorylation of caspase-9 by Akt also blocks the induction of apoptosis, and both Akt and NFκB can activate Bcl-2 to inhibit cytochrome c release from mitochondria [17]. Suppression of proapoptotic proteins such as Bax is also associated with the occurrence of drug resistance. In the clinical setting, upregulation of antiapoptotic proteins (i.e., Bcl-2) and downregulation of proapoptotic proteins (i.e., Bax) are found to be associated with poor prognosis of cancer patients [11, 18], which supports a causal role of apoptosis inhibition in the occurrence of cancer cell drug resistance.


## 2.3. Detoxification

GSH-GST system is one of the major detoxification mechanisms, which is in relevance to the development of drug resistance [19]. Levels of GSH and GST activity are in positive correlation with cancer stage [20]. Protein level of GSTπ, in particular, is found to be associated with chemoresistance in patients with different cancers [21–23]. In the clinical setting, GST gene polymorphisms are associated with the development of different cancers [24] and the response of cancer patients to chemotherapy [25]. These observations support a role of GSH-GST system in the regulation of cancer cell response to chemodrugs.GSH is a small peptide composed of glutamate, cysteine, and glycine. It is an important cellular antioxidant that can suppress oxidative stress to maintain normal cellular redox homeostasis, which relies on its conjugation properties of the sulfhydryl moiety of the cysteine residue. GSH has the ability to directly scavenge cellular reactive oxygen species in a nonenzymatic manner. Alternatively, it serves as a cofactor for GSH peroxidase in the reduction of H2O2 and other peroxide species. The GSTs are classical phase II metabolic enzymes including GSTπ. They can detoxify xenobiotics via conjugation of reduced GSH with the electrophilic center of a large spectrum of hydrophilic molecules. Although GSH-GST system helps in the maintenance of normal redox homeostasis and the protection against oxidative damage, it has adverse effect in chemotherapy, as it is also intimately involved in the detoxification of numerous xenobiotics. GST family of enzymes utilize GSH as a cofactor in the phase II metabolism of various chemotherapeutic agents, resulting in the formation of GSH-drug conjugates that are more water soluble than their parent compounds and therefore are easier for transporter-mediated efflux. Unfortunately, many chemodrugs are substrates of GSTs. This explains why elevated level/activity of intracellular GSH-GST system is often implicated in the development of cancer cell resistance to various chemodrugs [2].


## 3. Natural Products Overcome Cancer Cell Drug Resistance on Cell Line Models through Various Molecular Mechanisms

Chinese people have been treating diseases using Traditional Chinese Medicine for long, which typically involves the use of natural products in addition to acupuncture, moxibustion, and physiotherapy. Possibly due to this heritage, we are keen to use natural products to overcome cancer cell drug resistance. Wang and coworkers [26] treated bladder cancer T24/ADM cells by doxorubicin with or without osthole. They found that the IC50 of osthole was 76.5 μM and it was not toxic to the cells at the concentrations of 17 μM or below. However, at 17 μM, it was able to lower the IC50 of doxorubicin from 1.0 to 0.4 μM, resulting in an increase of drug sensitivity by 2.5 times. Nong and coworker [27] investigated the antidrug resistance effects of evodiamine using A549/DDP cell line. The compound was not toxic to both resistant and sensitive (A549) cells at the concentrations of 5 μg/mL or below. At 0.25 μg/mL, it lowered the IC50 of cisplatin from 76.7 to 6.7 μg/mL, resulting in an increase in the drug sensitivity of A549/DDP cells by 11.4 times. In mechanistic analysis, the authors found that evodiamine was able to decrease the mRNA levels of MDR1 and Bcl-2 and decrease the level of pIKKα, indicating that the compound acts on multiple pathways to overcome drug resistance. Celastrol also has significant antidrug resistance activity. In K562/A02 cells, it can increase the cell sensitivity to chemodrug by 117.9 times, concomitantly with a significant increase in intracellular drug concentration and a decrease in MDR1 protein level [28]. In another study, embelin was found to increase the sensitivity of drug resistant K562 cells to daunorubicin by 7.5 times [29].There are many more studies using cell line models to test the antidrug resistance activity of natural products. Some studies focus on antidrug resistance effect of compounds without examining the underlying mechanisms (Table1). Some others investigate the antidrug resistance activity of natural products and the mechanism of drug efflux (Table 2) or inhibition of apoptosis (Table 3). There are natural products that can overcome drug resistance and regulate different pathways, suggesting that they act on multiple molecules to achieve their biological activity (Table 4). Moreover, some compounds are found to target GSH-GST system. These include arsenic trioxide [30], neferine [31], quercetin [32], emodin [33], irisquinone [34], tetramethylpyrazine [35], and ganoderma lucidum polysaccharides [36].Table 1
Natural products that can overcome drug resistance without mechanistic information.
Compound name
Dose
Cell model
Chemodrug
IDS1
Reference
Single compound
4′-Methylether-scutellarein
20μg/mL
JAR/VP16
Etoposide
5.0
[61]
Dauricine
2.5μg/mL
K562/ADM
Doxorubicin
5.0
[62]
Dihydroartemisinin
0.3μM
A549/CDDP
Cisplatin
12.3
[63]
Ginsenoside Rh2
40μM
MCF/ADM
Doxorubicin
31.1
[64]
Isorhynchophylline
1.5–3μg/mL
A549/DDP
Various
7.2–24.3
[65–67]
Ligustrazine
2.6–10μg/mL
K562/ADM
Doxorubicin
6.0–178
[68, 69]
Matrine
50μg/mL
K562/ADM
Doxorubicin
2.2
[70]
Peiminine
20μg/mL
SGC7901/VCR
Various
6–27
[71]
Schizandrol A
25μM
HL60/ADR
Daunorubicin
8
[72]
Tanshinone II A
0.2μg/mL
MCF/ADM
Doxorubicin
2.5
[73]
Single herb extract
Eleutherococcus senticosus
200μg/mL
K562/ADR
Daunomycin
4.2
[74]
Andrographis paniculata
2.4μg/mL
CHT8/5FU
Various
2.1–2.2
[75]
Indigowoad root
31μg/mL
BEL7404/ADM
Doxorubicin
4.8
[76]
Formula extract
Danggui Buxue recipe
300μg/mL
SGC7901/ADR
Doxorubicin
2.8
[77]
Fufang Jinzi recipe
5μg/mL
K562/VCR
Vincristine
3.6
[78]
1IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.Table 2
Natural products that can overcome drug resistance and inhibit drug transporters.
Compound name
Dose
Drug target1
Cell model
Chemodrug
IDS2
Reference
Single compound
Apigenin
15μM
MDR1
HCT/5FU
5-Fluorouracil
5.8
[79]
Arsenic Trioxide
0.15–0.4μM
MDR1 and MRP
Various
Various
2.1–3.0
[80–82]
Artemisinin
40μM
MDR1
MCF7/ADR
Doxorubicin
3.6
[83]
Artesunate
20μg/mL
MDR1
SP2/0/ADM
Doxorubicin
4.2
[84]
Baicalin
20–300μg/mL
MDR1 and MRP1
Various
Doxorubicin
6.3–7.8
[85, 86]
Berbamine
20μM
MDR1
MCF7/ADR
Doxorubicin
28.3
[87]
Berberine
20μM
MDR1
HCT8/VCR
Vincristine
3.6
[88]
Carnosic acid
5μg/mL
MDR1
K562/A02
Doxorubicin
12.1
[89]
Chelerythrine
0.1μM
MDR1
MCF7/Taxel
Paclitaxel
5.9
[90]
Curcumin
2.5–25μM
MDR1
Various
Various
4.6–4.8
[91, 92]
Elemene
4–18μg/mL
MDR1 and MRP
Various
Various
3.1–4.1
[93–95]
Ephedrine
75μg/mL
MDR1
K562/A02
Daunorubicin
5.7
[96]
Epigallocatechin gallate
2–80μM
MDR1 and ABCG2
Various
Various
2.7–24.2
[97, 98]
Gambogic acid
4μg/mL
MDR1
SW480/L-OHP
Oxaliplatin
3.7
[99]
Ginsenoside Rb1
80μM
MDR1
HL60/VCR
Vincristine
2.7
[100]
Ginsenoside Rg3
10–40μg/mL
MDR1, MRP, and LRP
Various
Various
7.3–11
[101, 102]
Neferine
10–20μM
MDR1 and MRP
SGC7901/VCR
Various
3.3–43.8
[103–105]
Oridonin
3μM
MDR1
K562/A02
Various
9.2
[106]
Oxymatrine
0.8 mg/mL
MDR1
MCF7/ADM
Doxorubicin
3.3
[107]
Peimine
400μg/mL
LRP
A549/DDP
Cisplatin
3.7
[108]
Psoralen
20μg/mL
MDR1
MCF7/ADR
Doxorubicin
11.8
[109]
Quercetin
Various
MDR1 and MRP1
Various
Various
2.3–22.0
[110, 111]
Sodium norcantharidate
5μg/mL
MDR1 and MRP
A549/DPP
Cisplatin
2.0
[112]
Tetramethylpyrazine
200–320μg/mL
MDR1
Various
Doxorubicin
2.1–5.2
[113–115]
Tetrandrine
1μM
MDR1
Hep3B/ADM
Doxorubicin
12.7
[116]
Single herbal extract
Brucea Javanica
55.3–125μg/mL
MDR1 and MRP
Various
Various
2.1–5.8
[117, 118]
Cinobufacini
?
MDR1 and MRP1
Raji/ADR
Doxorubicin
255.7
[119]
Grape seed polyphenols
2.4–6.0μg/mL
MDR1
Various
Various
3.4–4.5
[120, 121]
Hyaluronate Oligomers
100μg/mL
MDR1 and MRP
MCF7/ADM
Doxorubicin
2.0
[122]
Jew ear
8–10μg/mL
MDR1 and MRP
Various
Various
2.2–5.6
[123–125]
Radix notoginseng
200μg/mL
MDR1
Various
Various
5.6
[126, 127]
Rhizoma pinelliae
6.5μg/mL
MDR1
K562/A02
Doxorubicin
3.6
[128]
Realgar
25μg/mL
MDR1
MCF7/ADM
Doxorubicin
2.8
[129]
Thallus laminariae
70–78μg/mL
MDR1
Various
Doxorubicin
4.7–5.0
[130, 130]
1Levels of protein or mRNA or both were quantified.
2IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.Table 3
Natural products that can overcome drug resistance and inhibit apoptosis signaling.
Compound name
Dose
Drug target1
Model cell
Chemodrug
IDS2
Reference
Single compound
Curcumin
10μM
Caspase-3
HCT8/5FU
5-Fluorouracil
10.1
[131]
Dihydroartemisinin
230 nM
Bcl-2, Bax, and Caspase-3
A549/DDP
Cisplatin
8.3
[132]
Elemene
10–30μg/mL
GSH, Bcl-2, and Bad
Various
Various
2.2–3.7
[133–135]
Emodin
30μM
p-EGFR and p-ERK
HCC827/GR
Gefitinib
6.0
[136]
Epigallocatechin gallate
80μM
Bcl-2 and Bax
K562/A02
Doxorubicin
24.2
[137]
Ginsenoside Rh2
10μM
A549/DDP
Cisplatin
3.5
[138]
Neferine
10μM
Bcl-2
SGC7901/VCR
Vincristine
43.8
[139]
Parthenolide
20μM
Survivin and Bcl-2
A549/GR
Gefitinib
8.7
[140]
Phenylpropanoid glycoside
40μg/mL
Caspase-3
LoVo/ADR
Doxorubicin
9.9
[141]
Retinoic acid
1μM
Bcl-2
MCF7/TAM
Tamoxifen
6.7
[142]
Tetrandrine
1.0μg/mL
Bcl-2 and Bax
BIU-87/ADM
Doxorubicin
2.2
[143]
Herbal extract
Realgar
15μg/mL
Bcl-2
MCF7/ADM
Doxorubicin
2.3
[144]
1Levels of protein or mRNA or both were quantified.
2IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.Table 4
Natural products that can overcome drug resistance and regulate multiple pathways.
Compound name
Dose
Pathways1
Cell model
Chemodrug
IDS2
Reference
Single compound
Arsenic trioxide
0.8μM
MDR1 and GST-π
SGC7901/ADR
Doxorubicin
2.1
[82]
Berbamine
20μM
MDR1 and survivin
K562/A02
Doxorubicin
41.2
[145]
Carnosic acid
25μM
MDR1 and Bcl-2
K562/A02
Doxorubicin
12.1
[146]
Curcumin
25μM
MRP and Bcl-2
HL60/ADR
Doxorubicin
4.2
[147]
Emodin
10μM
MRP1, Topo II b, GST-π, and Bcl-2
HL60/ADR
Doxorubicin
4.1
[148]
Honokiol
6.5μg/mL
MDR1 and NFkB
U937/ADR
Doxorubicin
2.2
[149]
Methylether-scutellarein
20μg/mL
ABC and apoptosis genes
JAR/VP16
Various
2.5–5.0
[150]
Quercetin
10μg/mL
MDR1 and survivin
A549/DDP
Cisplatin
3.5
[151]
Quercetin
40μM
ABC, Bcl-2, and SLC genes
K562/A
Doxorubicin
3.7
[152]
Quercetin
40μM
MDR1, MRP, GST-π, and H-ras
Bel-FU
5-Fluorouracil
2.4
[153]
Schizandrin B
10μM
MDR1, pPI3K, and pAKT
U-2 OS/ADR
Various
2.3–2.9
[154]
Schizandrin A
50μM
MDR1 and GSH
Various
Various
41.2–147.5
[155]
Sodium selenite
10μM
MDR and Bcl-2
K562/ADR
Doxorubicin
2.3
[156]
Tetrandrine
1μg/mL
MDR1, survivin, and caspase-3
BIU87/ADM
Doxorubicin
5.3
[157]
Herbal extract
Radix bupleuri
300μg/mL
MDR1 and TopoIIα
Bel-7402
Verapamil
15.6
[158]
Grape seed polyphenols
6μg/mL
MDR1 and Bcl-2
GBC/SD
Various
3.4–4.5
[159]
Tea polyphenols
7.5μg/mL
MRP and Bcl-2
HL60/VCR
Various
2.3–9.1
[160]
1Levels of protein or mRNA or both were quantified.
2IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.Fourteen single compounds are shown to be able to overcome cancer cell drug resistance for the first time. These include evodiamine, peiminine, isorhynchophylline, berberine, ephedrine, ginsenoside Rb1, oridonin, oxymatrine, methylether-scutellarein, sodium norcantharidate, phenylpropanoid glycoside, retinoic acid, schizandrin A, and baicalin (Tables1–4), which deserve further investigations. Also for the first time, the studies have revealed the antidrug resistance activities of the various herbal extracts (Tables 1–4).Some of these compounds (Tables1–4) are in clinical use for the management of various diseases. For example, oxymatrine is in clinical use to suppress replication of hepatitis B virus [37] and prevent hepatic fibrosis [38]. Berberine is commonly used to treat bacterial and viral infections as well as to increase insulin sensitivity and lower the level of blood sugar [39]. Ephedrine is used to regulate blood pressure [40]. Sodium norcantharidate is used alone or in combination with other established chemotherapeutic drugs to treat cancers [41]. Baicalin is useful in treating psoriasis [42].Some information has not been included in Tables1–4, which deserves specification: (1) in the reviewed studies (Tables 1–4), the compounds are commonly used in no-toxic or subtoxic concentrations; (2) the tested compounds can overcome drug resistance in a dose-dependent manner; (3) in some but not all studies, it has been shown that the drug resistance-related genes/proteins are upregulated in drug resistant cells compared to their drug sensitive counterparts, and the tested compounds lower the expression level of the drug resistance-associated genes/proteins in the resistant cells; (4) the tested compounds largely increase drug sensitivity of resistant cells, with no or weak effect on the drug sensitive counterparts, which suggests that the antidrug resistance activity of the compounds has a specificity; (5) some studies have demonstrated the antidrug resistance effects of the natural products on multiple cell line models treated with different chemodrugs; and (6) all of the mentioned herbs and some of the single compounds have been used in clinical settings in China in treating various diseases, which is not further discussed in detail.


## 4. Serum Pharmacology

Compounds are introduced to cell culture in thein vitro studies, and their actions may be different when they are appliedin vivo, since they will be subjected to metabolism in the latter condition. Serum pharmacological study provides a mean to address the issue, at least in part [43]. In this type of assay, animals are fed with compounds or herbal extracts over a short period of time, and serum samples are collected for bioactivity assayin vitro on cell line models. The outcomes are more likely to represent the bioactivity of compoundsin vivo. Usually, compounds are given to animal in an amount equivalent to that used in humans in terms of quantity per unit of body weight. Serum is often applied to cell culture at the concentrations between 5 and 20% in volume. At least 52 serum pharmacology studies are recorded in the Chinese database used for information acquisition, all of which use extract of herbal formulas, except one that uses extract of single herb extract, possibly due to the reason that herbal formulas rather than single herb are commonly used in the practice of Traditional Chinese Medicine. Deng and coworkers [44] investigated the antidrug resistance effect of Changweiqing. They fed rats with Changweiqing extract for 5 days and collected serum samples. In control groups, rats were given saline. The serum samples from the rats in the experimental group were found to be able to increase the sensitivity of drug resistant HCT8/V cells to cisplatin by 13 timesin vitro. The antidrug resistance effect of Changweiqing serum has also been observed on oral epidermoid carcinoma cell line KB-A-1. It increased the sensitivity of the drug resistant cells to doxorubicin in a dose-dependent manner, which reached 5.2 times at the concentration of 5% in cell culture medium [45]. Wenxia formula is another formula that can overcome drug resistance. Serum from animals fed with this formula extract can increase the sensitivity of A549/DDP cells to cisplatin by 2.5 times [46]. Five more serum pharmacology studies are listed in Table 5. The herbal compositions of these formulas are listed in Table 7. Moreover, these formulas have been used in the clinical setting in China to treat various diseases. Changweiqing, for example, is in clinical use to treat constipation [47], infection of Helicobacter pylori [48], and chronic gastritis [49].Table 5
Natural products overcome drug resistance in serum pharmacology studies.
Name
Dose (days)
Serum dose1
Cell model
Chemodrug
IDS2
Reference
Buzhong Yiqi Tang
5.7 g/kg (3)
15
A549/DDP
Cisplatin
3
[161]
Jiedu Huayu recipe
3 g/kg (3)
10
HL60/Adr
Doxorubicin
8.4
[162]
Scutellariae barbatae
14.1 g/kg (4)
0.5
K562/A02
Various
2.2–5.4
[163]
Shehuang Xiaoliu
29.7 g/kg (10)
20
Bel7402
Doxorubicin
8.3
[164]
Zedoary turmeric oil
0.8 mg/kg (3)
20
SGC7901/CDDP
Verapamil
6.1
[165]
1Percentage of serum being tested in addition to the conventional 10% of fetal bovine serum in cell culture.
2IDS, increase in drug sensitivity (x-fold).
IDS = IC50 in control group/IC50 in experimental group.


## 5. Overcome Drug Resistance in Animal Models

Since many natural compounds can overcome cancer cell drug resistancein vitro (Tables 1–4), it is logical to ask whether the bioactivities can be replicatedin vivo, that is, in animal models. Indeed, the effects have been shown in a number of studies in animal models. Zhang and coworker [50] built an experimental model of nude mice with xenograft of drug resistant HCT116/L-OHP cells and divided the mice into two groups. One was treated with oxaliplatin, which serves as the control. In the experimental group, mice were treated with oxaliplatin plus Changweiqing extract, 5 times a week for 3 weeks. Compared with the tumor size in the controls, The tumor size in mice treated with Changweiqing was reduced by 3.1 times on average, compared with that in the controls. Feng and coworker [51] treated mice bearing xenograft of drug resistant MCF-7/ADM cells with doxorubicin (control group) or doxorubicin plus extract of Huatan Sanjie formula (experimental group). Herbal extract was applied only twice, at days 8 and 15, respectively. At day 17, mice were sacrificed and tumor tissues were dissected. Compared to the controls, the mice in the experimental group had decreased in tumor tissue weight by 4.8-fold. Interestingly, the tumor tissues from the mice in the experimental group had increased level of doxorubicin and decreased protein level of MDR1. The data, taken together, suggest that the herbal extracts overcome the drug resistance of the tumor xenograft by inhibiting drug pump. In addition to herbal extracts, single compound is found to overcome drug resistancein vivo. In thein vitro study, epigallocatechin gallate (30 μg/mL) is not toxic to drug resistant KBV200 cells but increases their sensitivity to vincristine by 13 times, increases the intracellular vincristine concentration by 3 times, and reduces the intracellular MDR1 protein concentration. In mice model, the compound significantly increases the antitumor effect of vincristine and decreases the mRNA levels of MRD1 as well as LRP in tumor tissues [52]. Similarly, Puerarin was found to increase the tumor growth inhibition rate from 18.1% (treated with 5-fluorouracil, control group) to 56.7% (treated with 5-fluorouracil plus puerarin, experimental group) and decrease the protein levels of MDR1 and MRP in tumor tissues [53]. In nude mice with tumor xenograft (HCT8/VCR cells), curcumin increases the chemotherapeutic potential of vincristine and decreases the protein levels of MDR1 as well as survivin in the tumor cells [54]. Cepharanthine (4 μM) is not toxic to EAC/ADR cellsin vitro but can increase the cell sensitivity to doxorubicin by 13 times and inhibit NF-κB activity which is upregulated in the drug resistant cells. In mice model, the compound can increase the life span of mice by 75.4%. Wang [55] developed a mouse liver cancer cell line (Hca cells) model to investigate antidrug resistance effect of cepharanthine hydrochloride. The resistant cells have higher levels of MDR1 and MRP1 compared to their drug sensitive parental cells and are resistant to multiple chemodrugs such as etoposide, daunorubicin, and vincristine. In mice bearing drug resistant Hca cells, cepharanthine hydrochloride can inhibit the expression of the drug transporters and increase the intracellular concentration of chemodrugs as well as life span of animals. In mice bearing drug resistant S180 sarcoma cells, matrine (100 mg/kg a day for 10 days) reduces the protein levels of MDR1, LRP, and Topo II by 78%, 84%, and 65%, respectively [56]. Also in S180-bearing mice, tetrandrine reduces the protein level of MDR1, increases the protein levels of Fas and Trail, and enhances the tumor cell apoptosis [57]. These results indicate that the natural products are potent agents to overcome cancer cell drug resistancein vivo, by inhibiting molecules that mediate drug resistance.


## 6. Clinical Studies

The ultimate goal of laboratory investigations is to achieve clinical applications. In clinical studies, patients are commonly divided into two groups. Patients in control group receive conventional chemotherapy. Patients in treatment group receive conventional chemotherapy plus natural product(s). Hu and coworkers [58] investigated the effect ofFritillariae thunbergii in 90 acute leukemia patients and found that the patients in the treatment group had lower number of leukemia cells in bone marrow, decreased protein level of MDR1, and decreased remission rate, compared with patients in the control group. Li and coworkers [59] investigated the effect of theFritillariae thunbergii in 30 patients with acute leukemia patients who expressed high level of MDR1. The patients in the treatment group had lower protein level of MDR1 (3 times lower), higher therapy response rate (20% versus 55%), and lower percentage of leukemic cells in bone marrow (50% versus 26%). Zhao and coworker [60] recruited 36 patients with acute leukemia, who were positive to MRP protein. They performed real-time PCR to quantify bone marrow cell mRNA levels of MRP and β2M, and patients with MRP/β2M value equal to or greater than 0.3 were considered as MRP positive. The patients treated with ligustrazine injection (120 mg iv. daily for 15 days) were more likely to turn negative for MRP (45.5 versus 7.1%) and have lower percentage of leukemic cells in bone marrow (21.4 versus 55.6%). Some other clinical studies and benefits are included in Table 6. The compositions of formulas are shown in Table 7.Table 6
Clinical studies and benefits.
Disease (number of patients)
Treatment agent
Clinical benefit
Reference
Relapsed non-Hodgkin’s lymphoma (60)
Ligustrazine
Higher overall response rate
[166]
Breast cancer (76)
Chinese magnolcavine fruit
Increase in response rate, delayed remission, and increase in the MRP negativity rate
[167]
Advanced gastrointestinal cancer (54)
Changweiqing formula
Higher response rate and Karnofsky scoreLonger survival timeLower level of MDR1 in blood cells
[168]
Gastric cancer, stages II-III (30)
Didang formula
Higher response rate and better life qualityLower level of MDR1 in blood cells
[169]
Liver cancer (71)
Xiaochaihu formula
Higher response rate and lower protein level of MDR1 in cancer tissue
[170]
Gastric cancer, stages II-III (60)
Shenqi Jianwei formula
Higher response rate, lower level of lower of CEA, and higher Karnofsky score
[171]
Breast cancer (60)
Pingxiao formula
Higher response rate and lower protein levels of MDR1 and GSTπ in cancer tissues
[172]
Breast cancer (53)
Fukangling capsule
Higher response rate and lower protein levels of MDR1 and GSTπ in cancer tissues
[173]
Non-small cell lung cancer (60)
Qiankun capsule
Lower level of blood TGF-α and lower number of PCNA positive cells as well as lower protein levels of LRP and MRP in cancer tissue
[174]
Breast cancer, stages II-III (33)
Fukangling capsule
Higher response rate and lower protein level of MDR1 in cancer tissue
[174]Table 7
Major composition of formulas.
Name of formula
Major composition
Changweiqing
Astragalus membranaceus,   Atractylodes macrocephala Koidz,   Radix Codonopsis Pilosulae,   Polyporus,   Coix chinensis Tod,   Fructus Akebiae Trifoliatae,   Vitis quinquangularis Rehd,andSargentodoxa cuneata(Oliv.) Rehd. et Wils
Wenxia Fang
Rhizoma et Radix Rhei Palmat,   Aconitum carmichaeli Debx,   Panax ginsengC. A. Mey,and Angelica sinensis
Buzhong Yiqi
Astragalus membranaceus,   Radix Glycyrrhizae,   Panax ginsengC. A. Mey,   Angelica sinensis,   Pericarpium Citri Reticulatae,   Cimicifuga foetidaL.,   Radix Bupleuri,andAtractylodes macrocephala Koidz
Jiedu Huayu
Indigo Naturalis,   Asarum sagittarioidesC. F. Liang,   Rhizoma Paridis Chinensis, Curcuma zedoaria (Christm.)  Rosc.,   Rhizoma Chuanxiong,   Radix Salviae Miltiorrhizae,andFructus Psoraleae
Shehuang Xiaoliu
Moschus berezovskii Flerov,   Bos taurus domesticus Gmelin,   Curcuma zedoaria (Christm.)  Rosc.,   Astragalus membranaceus,   Radix Codonopsis Pilosulae,   Scutellaria barbataD. Don.,and Hedyotis diffusa
Didang
Hirudo,    Tabanus,   Semen Persicae,andRhizoma et Radix Rhei Palmat
Xiaochaihu
Viola philippicaCar.,   Hedyotis diffusa,   Pyrrosia lingua(Thunb.)Farwell,   Zaojiaoci  (Spina Gleditsiae),   Manis pentadactyla Linnaeus,andSmilax glabraRoxb.
Shenqi Jianwei
Radix Codonopsis Pilosulae,   Astragalus membranaceus,   Atractylodes macrocephala Koidz,   Angelica sinensis,   Radix Paeoniae Alba,   Smilax chinaL.,   Taraxacum mongolicum,   Crataegus pinnatifida,   Perilla frutescens (L.) Britton.,   Radix Aristolochiae,andPericarpium Citri Reticulatae
Pingxiao
Curcuma longaL.,   Agrimonia pilosaLedeb.,   Trogopterus xanthipesMilne-Edwards,   Alumen,   Nitrum,   Toxicodendron vernicifluum(Stokes) F. A. Barkl.,   Bitter Orange Fructus Aurantii,andStrychnos nux-vomicaLinn.
Fukangling capsule
Panax ginsengC. A. Mey,   Astragalus membranaceus,   Ganodermae Lucidi,   Rhizoma Polygonati,   Radix Glehniae,andFructus Schisandrae Chinensis
Qiankun capsule
Radix Codonopsis Pilosulae,   Radix Rehmanniae,   Astragalus membranaceus,   Fructus Psoraleae,   Furctus Lycii barbari,   Fructus Ligustri Lucidi,   Asarum sagittarioidesC. F. Liang,   Rhizoma Dioscoreae Bulbiferae,   Indigo Naturalis,   Herba Cirsii Setosi,   Panax notoginseng,   Lobed Kudzuvine Root,andBos taurus domesticus Gmelin
Huatan Sanjie
Smilax china,   Rhizoma pinelliae,   Bulbus Fritillariae Thunbergii,   Coix chinensis Tod,   Pollen,andCurcuma zedoaria(Christm.) Rosc.


## 7. Conclusion

Drug resistance explains a big part of failure in cancer chemotherapy. Despite the efforts to overcome cancer cell drug resistance, there is no satisfactory solution so far. Natural products provide a vast pool for screening for drugs including candidate compounds to overcome drug resistance. Although the studies included in this review are not particularly rich in scientific details, they show that many natural products, used alone or in combination, are potent inhibitors of drug resistance under laboratory conditions and in clinical setting, which provides informative original observations (including many first time reports) for the scientific and industrial communities. Some single compounds and herbal ones as well as all of the herbal formulas have already been used clinically in treating various diseases including cancer. Future studies may identify natural products for clinical management of cancer cell drug resistance.



---

*Source: 767136-2015-09-01.xml*